Salud Pública y Materno-Infantil
Departamento
![Foto de Salud Pública y Materno-Infantil](/img/noimage.png)
![Foto de Medical Research Council](/img/noimage_org.png)
Medical Research Council
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de Medical Research Council (16)
2023
-
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
The Lancet Child and Adolescent Health, Vol. 7, Núm. 10, pp. 718-727
2022
-
Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial
BMC Medical Research Methodology, Vol. 22, Núm. 1
-
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
The Lancet HIV, Vol. 9, Núm. 5, pp. e341-e352
-
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
The Lancet HIV, Vol. 9, Núm. 9, pp. e638-e648
2021
-
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
New England Journal of Medicine, Vol. 385, Núm. 27, pp. 2531-2543
2018
-
Microbial translocation does not drive immune activation in ugandan children infected with HIV
Journal of Infectious Diseases, Vol. 219, Núm. 1, pp. 89-100
-
Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life
HIV Medicine, Vol. 19, Núm. 1, pp. e1-e42
2016
2015
-
Early antiretroviral therapy in children perinatally infected with HIV: A unique opportunity to implement immunotherapeutic approaches to prolong viral remission
The Lancet Infectious Diseases, Vol. 15, Núm. 9, pp. 1108-1114
2013
-
Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children
AIDS and Behavior, Vol. 17, Núm. 1, pp. 193-202
-
Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants
AIDS, Vol. 27, Núm. 6, pp. 991-1000
2012
-
Migrant mortality from diabetes mellitus across Europe: The importance of socio-economic change
European Journal of Epidemiology, Vol. 27, Núm. 2, pp. 109-117
2011
-
Risk of triple-class virological failure in children with HIV: A retrospective cohort study
The Lancet, Vol. 377, Núm. 9777, pp. 1580-1587
2004
-
Monitoring of trends in socioeconomic inequalities in mortality: Experiences from a European project
Demographic Research, Vol. 10, Núm. SUPPL. 2, pp. 229-254
2002
-
Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial
Journal of Infectious Diseases, Vol. 186, Núm. 3, pp. 312-320
-
PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection
HIV Medicine, Vol. 3, Núm. 3, pp. 215-226